Related Experiment Video
Updated: Nov 11, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer
Michael Sun1, Muhammad Junaid Niaz2, Muhammad Obaid Niaz3
1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 525 East 68th Street, Box 403, New York, NY, 10065, USA.
Purpose Of Review:
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). This review describes the available data with PSMA TRT.
Recent Findings:
Conjugates used for PSMA TRT include antibodies or small molecules PSMA-radiolabeled with beta (most commonly 177Lu) or alpha emitters (commonly 225Ac). 177Lu-J591 demonstrated accurate targeting of known metastatic sites, based on post-treatment scintigraphy, in study populations that were not selected for PSMA expression, with evidence of dose-response and dose-limiting myelosuppression. Early phase studies of 177Lu-PSMA-617 have demonstrated favorable adverse event profiles and signs of clinical activity as evidenced by PSA responses and other short-term outcomes. A phase II randomized study of 177Lu-PSMA-617 showed a superior PSA50 response rate (66 vs 37%) over cabazitaxel in patients with docetaxel-pretreated, progressive mCRPC selected by PSMA and FDG PET/CT scans. PSMA TRT is emerging as a promising investigational therapy for mCRPC. The first randomized data with 177Lu-PSMA-617 (phase 2) have been presented, and the first phase 3 trial has completed accrual with radiographic progression-free and overall survival as dual primary endpoints. Multiple additional phase 3 trials of PSMA-TRT are starting and studies investigating optimal patient selection and combination therapy continue.
Insights
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) shows promise for metastatic castration-resistant prostate cancer (mCRPC). Studies indicate favorable outcomes and ongoing trials are evaluating its efficacy and patient selection for mCRPC treatment.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
- Prostate-specific membrane antigen (PSMA) is a highly expressed target in mCRPC.
- PSMA-targeted radionuclide therapy (TRT) offers a novel therapeutic approach.
Purpose of the Study:
- To review available data on PSMA-targeted radionuclide therapy for mCRPC.
- To summarize recent findings from clinical studies involving PSMA TRT.
Main Methods:
- Review of existing literature and clinical trial data on PSMA TRT.
- Analysis of conjugates used in PSMA TRT, including antibodies and small molecules labeled with beta or alpha emitters.
- Evaluation of clinical outcomes, safety profiles, and patient selection strategies.
Main Results:
- 177Lu-J591 demonstrated accurate targeting and dose-response, with dose-limiting myelosuppression.
- Early phase studies of 177Lu-PSMA-617 showed favorable safety and clinical activity (PSA responses).
- A phase II randomized study of 177Lu-PSMA-617 demonstrated superior PSA50 response rates compared to cabazitaxel in pretreated mCRPC patients.
Conclusions:
- PSMA TRT is an emerging and promising investigational therapy for mCRPC.
- Phase 3 trials are underway, with initial data suggesting efficacy.
- Ongoing research focuses on optimal patient selection and combination therapies for PSMA TRT.
